BerGenBio Collaborates with Tempus to Potentially Accelerate Development in STK11m NSCLC August 27, 2024
TROP2-ADC SKB264 (sac-TMT) Second NDA Accepted by NPMA for locally advanced or metastatic EGFR-mutant NSCLC August 27, 2024
FDA approves Imfinzi + chemo for treatment of adult patients with resectable early-stage (IIA-IIIB) EGFR/ALK WT NSCLC August 22, 2024
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510 and IMM27M August 7, 2024
FDA Advisory Committee reviewed Imfinzi for treatment of resectable NSCLC based on AEGEAN Ph 3 trial results July 30, 2024
Positive treatment updates announced from Ph 2 clinical trial, THIO-101, of THIO + cemiplimab (Libtayo®) in heavily pre-treated patients with advanced NSCLC July 30, 2024
CHMP recommends RYBREVANT + chemo for the treatment of adult patients with advanced EGFR-mutated NSCLC after failure of prior therapy July 30, 2024
Positive feedback received from FDA on the planned TACTI-004 Ph 3 trial of eftilagimod alfa + KEYTRUDA + chemo for the treatment of 1L NSCLC July 30, 2024
Positive Interim Ph 2 Monotherapy Expansion Data for IDE397 in MTAP-Deletion Urothelial and Lung Cancer Announced July 17, 2024
FAILED TRIAL: Ph 2/3 SKYSCRAPER-06 trial of tiragolumab, Tecentriq and chemo did not meet the primary endpoints of PFS at primary analysis and OS at first interim analysis July 9, 2024
RYBREVANT (amivantamab) + chemo approved in the EU for 1L treatment of patients with advanced NSCLC with activating EGFR ex 20 insertion mutations July 9, 2024
Focus on vebreltinib study enrollment for NSCLC patients with Met Amplification mutations announced July 9, 2024
Patritumab Deruxtecan BLA Submission Receives CRL from FDA Due to Inspection Findings at Third-Party Manufacturer July 1, 2024
FAILED TRIAL: ADJUVANT BR.31 Ph 3 trial of Imfinzi (durvalumab) did not achieve statistical significance for the primary endpoint of DFS vs placebo in early-stage (IB-IIIA) NSCLC July 1, 2024
GALAXIES Lung-301 Ph 3 study of Belrestotug and Dostarlimab in 1L Unresectable Locally Advanced/Metastatic PD-L1 Selected NSCLC initiated June 25, 2024
